Fontana, E., Williams, A., Falchook, G., Lakhani, N., Evans, T. R. J., Gondi, V., Iwamoto, F., McKean, M., Symeonides, S., Butowski, N., McLaren, A., Henry, J., Buerki, R., Rotolo, J., Capiaux, G., Michel, R., Kaesshaefer, S., Wiegert, E., & Bexon, A. (2022). Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors. European Journal of Cancer, 174, S82–S83. https://doi.org/10.1016/s0959-8049(22)01018-8